Investigators revealed the development of a non-invasive molecular test utilizing gene expression differences in skin diseases such as atopic dermatitis, psoriasis, and mycosis fungoides, with the potential to accurately diagnose and identify super-responders to targeted systemic therapies.
Alice Gottlieb, MD, PhD, put a spotlight on recent studies and the current psoriasis treatment armamentarium for dermatology clinicians to consider.
Susan Taylor, MD, provided insight into epidemiology, patient quality of life, clinical presentation, therapies, and more at Masterclasses in Dermatology.
Peter Lio, MD, shared alternative medicine approaches and resources that dermatologists and patients can utilize for various skin conditions.
The 2-GEP test is made of 2 biomarkers, LINC00518 and PRAME.
ICYMI, this week we had news about the National Rosacea Society's Seal of Acceptance Program, Dermavant's submitted sNDA for tapinarof cream 1% to treat AD, Galderma's accepted BLA for nemolizumab for the treatment of prurigo nodularis and AD, and more.
Japan is the first country in the world to approve dupilumab for the treatment of chronic spontaneous urticaria (CSU).
Dive into a complex case report of a 29-year-old African American male patient with Fitzpatrick skin type V with a 6-month reported history of vitiligo on his lips.
An investigation into skin changes at the cellular level provides insight into hyaluronic acid’s benefits.
The combination therapy did not yield any effect in patients with non-segmental vitiligo and prompts additional large studies prior to conclusive efficacy.
The IFPA Forum Roadmap for Asia outlines key advocacy demands and practical strategies to improve psoriatic care throughout the continent.
Learn what makes the Masterclasses in Dermatology conference a unique educational opportunity, and take a quick poll to tell us what you want to learn.
We want to know your thoughts on the recent guidelines. Share with us by answering our poll or emailing us at [email protected].
In an interview with Dermatology Times, the executive director of Pediatric Dermatology Research Alliance (PeDRA) discusses the group's growth since 2012 and what it can offer practicing dermatologists, researchers, students, and patients.
The test may help patients with melanoma safely avoid a sentinel lymph node biopsy.
In this month’s Cosmetic Conundrums column, explore skin barrier assessments, skin moisturization tests, and how to measure skin firmness.
New data on the devices will be available at the 2024 American Academy of Dermatology Annual Meeting.
Among the many sessions to be held at the Winter Clinical Miami 2024 Conference in Miami Beach, Florida, several Dermatology Times Editorial Advisory Board members are preparing to share their knowledge and insights.
Click here to answer our poll about the upcoming conference.
An analysis of popular self-tanners revealed that more than half of them contained at least 10 potential allergens, and some contained 20 or more.
A case report examined an incidence of storiform collagenoma, also known as sclerotic fibroma, associated with Cowden syndrome in a patient. This occurrence is considered rare.
Researchers noted that this study's findings are consistent with prior epidemiologic data.
Click here to answer our poll about the upcoming conference in Puerto Rico.
The FDA has also granted nemolizumab Priority Review for prurigo nodularis.
The resubmission follows the Complete Response Letter Citius received from the US FDA in July of 2023.
This week’s collection of the latest dermatologic studies covers the causal relationship between lipid-related metabolites and androgenic alopecia, contact allergens in self-tanning products, a retrospective cross-sectional analysis of vitiligo patients in Canada, and combining systemic anti-PD-1 treatment with adjuvant ablative fractional laser in a mouse model of cutaneous SCC.
Tapinarof cream demonstrated highly statistically significant improvement in the primary end point of vIGA-AD treatment success over vehicle at week 8.
Patients treated with the ointment showed improvement in lesional percentage body surface area.
In this week’s Pointers With Portela, the 208SkinDoc discusses the recent trend of tweens buying excessive skin care.
Artax announced that safety and efficacy data is expected in the second half of the year.
